drugset / Trial / NCT00797225
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418) compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months of treatment on elagolix.
Timeline
- Start
- 2008-11-26
- Primary completion
- 2010-02-24
- Completion
- 2010-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elagolix | Small molecule | 150 mg | Oral |
| Subject | Elagolix | Small molecule | 250 mg | Oral |
| Subject | Leuprorelin Acetate Depot | Unknown | 3.75 mg | Intramuscular |